213 related articles for article (PubMed ID: 34021667)
21. Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT.
Kuyumcu S; Has-Simsek D; Iliaz R; Sanli Y; Buyukkaya F; Akyuz F; Turkmen C
Clin Nucl Med; 2019 Sep; 44(9):702-706. PubMed ID: 31348076
[TBL] [Abstract][Full Text] [Related]
22. Head-to-head comparison of [
Souza SPM; Frasson FC; Takahashi MES; Duarte GBO; Castro VP; Pericole FV; Velloso LA; De Souza CA; Lorand-Metze I; Santos AO; Ramos CD
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2432-2440. PubMed ID: 36988710
[TBL] [Abstract][Full Text] [Related]
23. Head-to-head comparison of [
Wang G; Li L; Wang J; Zang J; Chen J; Xiao Y; Fan X; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1499-1509. PubMed ID: 36600099
[TBL] [Abstract][Full Text] [Related]
24. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
25. Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.
Röhrich M; Huang K; Schrimpf D; Albert NL; Hielscher T; von Deimling A; Schüller U; Dimitrakopoulou-Strauss A; Haberkorn U
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1573-1584. PubMed ID: 29732524
[TBL] [Abstract][Full Text] [Related]
26. One-day protocol for
Chang Y; Donglan Y; Xinchong S; Ganhua L; Bing Z; Yao L; Rutong Z; Qiao H; Xiangsong Z
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(2):68-74. PubMed ID: 32005511
[TBL] [Abstract][Full Text] [Related]
27. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
[TBL] [Abstract][Full Text] [Related]
28. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
29.
Liu C; Liu T; Zhang N; Liu Y; Li N; Du P; Yang Y; Liu M; Gong K; Yang X; Zhu H; Yan K; Yang Z
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1852-1861. PubMed ID: 29717333
[TBL] [Abstract][Full Text] [Related]
30. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
31. Validation of 18F-FDG PET at conventional and delayed intervals for the discrimination of high-grade from low-grade gliomas: a stereotactic PET and MRI study.
Mertens K; Acou M; Van Hauwe J; De Ruyck I; Van den Broecke C; Kalala JP; D'Asseler Y; Goethals I
Clin Nucl Med; 2013 Jul; 38(7):495-500. PubMed ID: 23640217
[TBL] [Abstract][Full Text] [Related]
32. Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer.
Zhou X; Li Y; Jiang X; Wang X; Chen S; Shen T; You J; Lu H; Liao H; Li Z; Cheng Z
Front Oncol; 2020; 10():585213. PubMed ID: 33604285
[TBL] [Abstract][Full Text] [Related]
33. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
34. Comparison of dual-time point 18F-FDG PET/CT tumor-to-background ratio, intraoperative 5-aminolevulinic acid fluorescence scale, and Ki-67 index in high-grade glioma.
Kim YI; Cho KG; Jang SJ
Medicine (Baltimore); 2019 Feb; 98(8):e14397. PubMed ID: 30813140
[TBL] [Abstract][Full Text] [Related]
35. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic and prognostic role of combined [
Albano D; Dondi F; Bauckneht M; Albertelli M; Durmo R; Filice A; Versari A; Morbelli S; Berruti A; Bertagna F
Eur Radiol; 2023 Jun; 33(6):4167-4177. PubMed ID: 36482218
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to
Adnan A; Basu S
J Nucl Med Technol; 2020 Jun; 48(2):148-153. PubMed ID: 32111660
[TBL] [Abstract][Full Text] [Related]
38. The Heterogeneous Metabolic Patterns of Ganglia in
Shi Y; Wu JG; Xu L; Zhu Y; Wang Y; Huang G; Liu J; Chen R
Front Oncol; 2021; 11():666308. PubMed ID: 33968772
[TBL] [Abstract][Full Text] [Related]
39.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
40. Head-to-head intra-individual comparison of biodistribution and tumor uptake of
Giesel FL; Kratochwil C; Schlittenhardt J; Dendl K; Eiber M; Staudinger F; Kessler L; Fendler WP; Lindner T; Koerber SA; Cardinale J; Sennung D; Roehrich M; Debus J; Sathekge M; Haberkorn U; Calais J; Serfling S; Buck AL
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4377-4385. PubMed ID: 34137945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
